Lexaria Bioscience Corp. LEXX Archives - Page 28 of 39

FridayApr 29, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands its Patent Portfolio With New Patent for Antiviral Drug Delivery with DehydraTECH

Lexaria just received another patent for DehydraTECH(TM): this time for the enhanced delivery of antiviral drugs This becomes the company’s 25th patent granted worldwide and the 10th granted in the U.S. It adds to the company’s growing patent portfolio, which also consists of ~50 pending patents worldwide Over the 2022 calendar year, the company seeks to also pursue regulatory and commercial advancement In 2016, Lexaria Bioscience (NASDAQ: LEXX) received its first United States patent grant and over the years, the company has been aggressive at broadening its patent suite, a move which it has attributed to refining the patent claims…

ThursdayApr 28, 2022 3:01 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform

Lexaria Bioscience Corp. (NASDAQ: LEXX) is aware of the need to continuously improve its understanding of the capabilities and potential applications of its patented DehydraTECH(TM) drug delivery technology. This informs its long-held commitment to its applied research and development (“R&D”) programs. “So far, the company’s research journey has involved a series of controlled and well-designed in vitro preclinical testing and in vivo animal and human clinical studies…. Still, Lexaria is unrelenting in its pursuit of comprehensive datasets that would answer many questions the company expects to face from potential commercial partners or regulators and is, in fact, expanding its research.…

WednesdayApr 27, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Fourth Human Study for Reducing Hypertension, Reports Positive Outcome of Third Human Study’s Data

Global drug delivery innovator Lexaria Bioscience is researching the ability of its patented DehydraTECH(TM) technology to improve the performance of a number of prescription drugs Lexaria is a world leader in the investigation of a DehydraTECH-processed cannabidiol (“CBD”) to potentially treat high blood pressure (hypertension), and study outcomes thus far have rendered positive results on effectiveness and patient tolerance The company is building a scorecard of data to support its planned FDA application for formal, registered clinical testing under the Investigational New Drug (“IND”) process Lexaria recently completed all data analyses of its HYPER-H21-3 study examining DehydraTECH-CBD’s ability to reduce…

MondayApr 25, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices

Lexaria expects to begin dosing this summer as part of a human nicotine study, NIC-H22-1, to compare DehydraTECH-nicotine pouch performance to that of existing leading brands such as ON! and Zyn So far, the company’s animal studies have evidenced that the technology delivers outstanding results, including faster delivery, an increase in the quantity of peak nicotine delivered, higher brain levels of nicotine, and enhanced bioavailability In its most recent study, Lexaria established that DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls Lexaria’s research aims to…

ThursdayApr 21, 2022 2:04 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs. According to the update, Lexaria has received notification from the United States Patent and Trademark Office that patent 11,311,559 for “Compositions and Methods for Enhanced Delivery of Antiviral Agents” will be issued to the company on April 26, 2022. “This will be our 25th patent granted worldwide and another validation of the versatility of our DehydraTECH drug delivery technology,” said Chris Bunka, CEO of Lexaria. “This new…

TuesdayApr 19, 2022 2:58 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has begun its multi-week human clinical hypertension study. The randomized, double blinded, placebo-controlled, cross-over study in 60 people, HYPER-H21-4, is the most comprehensive study ever undertaken by Lexaria. HYPER-H21-4 is designed to enhance Lexaria’s probability of success with its expected subsequent Investigational New Drug (“IND”) application filing to seek U.S. Food and Drug Administration (“FDA”) approval to commence registered clinical testing at phase I level or higher, to be determined in consultation with the FDA. The human study is also expected to enhance Lexaria’s…

MondayApr 18, 2022 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Advances its Human Nicotine Study and Announces New Nicotine Formulation Creation and Evaluation Program with Altria

Lexaria’s patented DehydraTECH(TM) technology has proven, in the NIC-A21-1 animal study, to be 10-20 times faster in reaching peak delivery of nicotine to the bloodstream than controls The company hopes to affirm this in the NIC-H22-1 human nicotine study as their DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn Lexaria has separately announced new agreements with Altria that will see the company receive a fee to provide certain DehydraTECH powder-based nicotine formulations that Altria will evaluate The company hopes that this, coupled with the human clinical study,…

ThursdayApr 14, 2022 12:49 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released data from its HYPER-H21-3 human study. The company noted that data from its simulated pulmonary hypertension clinical study indicate positive safety and efficacy findings. Specifically, results show a tendency (p=0.1) during 15 minutes of simulated low levels of oxygen (hypoxia) for reduced pulmonary artery systolic pressure (“PASP”) with DehydraTECH-CBD treatment versus placebo. According to the announcement, PASP was significantly attenuated by about 5 mmHg or 41% overall (p=0.045) in male participants, which could indicate potential differences by sex in responsiveness to CBD treatment under hypoxic stress conditions. The…

TuesdayApr 12, 2022 1:03 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a minimum 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study to compare Lexaria's DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. Lexaria hopes to evidence that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to brands currently on the market. The study’s primary objective is data collection…

TuesdayApr 12, 2022 9:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX): A Review of Its Research Developments

Lexaria Bioscience, the global innovator behind DehydraTECH drug delivery technology, has continuously focused on research into its patented technology The company has conducted both in vitro testing and in vivo animal and human testing to evaluate the ability of DehydraTECH to improve the delivery of various APIs (active pharmaceutical ingredients) Lexaria has multiple other studies lined up aimed at building sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation As it moves toward national and international implementation and commercialization of its patented DehydraTECH(TM) drug delivery technology, Lexaria Bioscience (NASDAQ: LEXX) is aware of the need…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX